期刊文献+

肺癌特异性靶向小分子多肽的核素分子探针的制备 被引量:5

Preparation of Radiolabeling Small Molecular Peptide Probe for Specific Targeting Lung Cancer
下载PDF
导出
摘要 目的:研究用NHS-MAG3作为双功能螯合剂进行99mTc标记针对肺癌特异性靶向小分子多肽的核素分子探针的制备方法。方法:利用组合化学肽库技术筛选得到与非小细胞肺癌(A549)发生特异性结合的小分子多肽cNGQGEQc,在合成多肽的过程中直接完成多肽与双功能螯合剂NHS-MAG3的偶联,然后采用氯化亚锡直接进行99mTc的标记,并采用正交设计法进行99mTc最佳标记条件的摸索,纸层析法测定标记率,并观察99mTc标记小分子多肽的体外稳定性。结果:在固相法合成小分子多肽的过程中直接完成NHS-MAG3的联接,简化了偶联步骤,提高了偶联产率。最佳标记条件下标记率约为85%,经HPLC纯化后放化纯度>95%,且在室温条件下和血清中具有较好的体外稳定性。结论:以NHS-MAG3作为双功能螯合剂,用99mTc标记小分子多肽cNGQGEQc,具有良好的标记率和体外稳定性,可满足后续进一步的体内、外实验要求。 Objective To establish a radiolabelling method of specific small molecule peptide for lung cancer targeting with 99mTc by means of NHS-MAG3 as bifunctional chelating agents.Methods The combinatorial library technique was used for screening small molecule peptide specific binding to non-small cell lung cancer cell(A549).Peptide sequence of cNGQGEQc was identified.Chelant NHS-NAG3 was directly conjugated with peptide cNGQGEQc during the synthesis of cNGQGEQc.The optimal labeling conditions and stability in vitro were investigated.Labeling rates was determined by paper chromatography.Results The couple method of NHS-MAG3 with peptide cNGQGEQc by solid-phase synthesis was simplified and improved the couple efficiency.Peptide cNGQGEQc was successfully radiolabeled with 99mTc and the labeling ratio of 85% was obtained.The radiochemical purity was higher than 95% by HPLC purification.The labeled compounds of 99mTc-MAG3-cNGQGEQc was stable in vitro at room temperature.Conclusion It is feasible for coupling of NHS-MAG3 to peptide cNGQGEQc and its radiolabeling with high efficiency and better stability in vitro.It appears to be suitable for further experiments requirement in vivo and in vitro application.
出处 《放射免疫学杂志》 CAS 2011年第4期361-363,共3页 Journal of Radioimmanology
基金 国家自然科学基金(30770601) 国家教育部博士点基金(20094433110012) 广东省中国科学院全面战略合作项目(2009B091300130) 南方医院院长基金(2009B021)资助
关键词 肺癌 多肽 放射性标记 lung cancer polypeptide radiolabeling
  • 相关文献

参考文献6

二级参考文献88

  • 1郭琳琅,郭颖,DERICK LAU,肖莎,许寅超,申洪.一种特异性识别小细胞肺癌细胞的小分子肽[J].生物化学与生物物理进展,2006,33(6):562-566. 被引量:2
  • 2Krenning EP, Teunissen JJ, Valkema R, et al. Molecular radiotherapy with somatostatin analogs for (neuro-) endocrine tumors[ J ]. J Endocrinol Invest, 2005,28 (suppl 11 ) :146-150.
  • 3Kwekkeboom D, Krerming EP and de Jong M. Pepfide receptor imaging and therapy[J]. J Nucl Med, 2000,41(10) :1704-1713.
  • 4Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [ In-DTPA] octreotide: the Rotterdam experience[J]. Semin Nucl Meal, 2002,32(2) :110-122.
  • 5Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with ^90Y-DOTATOC in association with amino acid infusion: a phase Ⅰ study[J]. EurJ Nucl Med Mol Imaging, 2003,30(2) :207-216.
  • 6Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [ ^90Y-DOTA^0, Tyr^3 ] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors [J]. Semin Nucl Med, 2006,36(2) :14%156.
  • 7Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq ^90Y-DOTATOC[J]. J Nucl Med, 2002,43(5) :610-616.
  • 8Chind M, Bodei L, Cremonesi M, et al. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European institute of oncology group[J]. Semin Nucl Med, 2002,32 (2) :141-147.
  • 9van Essen M, Krenning EP, de Jong M, et al. Peptide receptor radionuelide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive turnouts[J]. Acta Ontology, 2007,46 (6) : 723 -734.
  • 10de Jong M, Breernan WA, Valkema R, et al. Combination radionuelide therapy using ^177 Lu-and ^90Y-labeled somatostatin analogs[ J ]. J Nuel Med, 2005,46(Suppl 1) :13S-17S.

共引文献12

同被引文献29

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部